Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 26, 2013

Kemwell Biopharma Acquires Cirrus Pharmaceuticals

  • Bangalore, India-based biopharmaceutical contract services company Kemwell Biopharma has acquired contract development services firm Cirrus Pharmaceuticals, which is based in Research Triangle Park, NC. Financial terms were not disclosed.

    Cirrus was established in 1997 and offers an array of R&D services including physical and chemical characterization, formulation development, stability testing, container/closure selection, process development, scale-up and technical transfer for inhaled, nasal, oral, parenteral, topical, and transdermal products. The firm also offers stand-alone services, such as stability studies.

    “The acquisition will transform Cirrus into a global player in R&D services by significantly strengthening our capabilities in inhalation R&D and increasing offerings in other areas such as oral solids dosage forms,” the firm’s president, Anthony Hickey, Ph.D., said in a statement.

    Added Kemwell’s chairman, Anurag Bagaria: “Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development. Kemwell will now provide customers with a complete solution from early development in the U.S. to commercial manufacturing in Kemwell's EMA-, FDA-, and PMD-approved facilities in India and Sweden.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »